Saum Ghodoussipour, MD

Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.

In an expert-led review of pivotal clinical trial data presented at the 2026 ASCO Annual Meeting, CancerNetwork® spoke with oncology experts in the renal cell carcinoma (RCC), Merkel cell carcinoma, and chronic myeloid leukemia (CML) spaces to break down key abstracts at the conference.

Considering the toxicity burden of dual checkpoint inhibition for adjuvant RCC, Saum Ghodoussipour, MD, posited potential alternatives in the space.

Saum Ghodoussipour, MD, PhD, dissected the contrasting outcomes between adjuvant durvalumab plus tremelimumab compared with durvalumab alone in RCC.